Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DeliChoP

Financiado

Drug DELIvery to the brain via CHOroid Plexus targeting

CNS disorders, e.g. brain cancer and Alzheimer’s disease, are the most common, debilitating, and underserved diseases. CNS drugs have historically suffered from considerably lower success rates during development than those for no... ver más

28/02/2029

VLAAMS INSTITUUT...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-31

ERC-2023-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

2.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-108806RB-I00 APROXIMACION SINERGICA AL DESARROLLO DE TERAPIAS PARA TUMORE... 242K€ Cerrado

Beyond the BBB Nerve Growth Factor Delivery into the Brain – focus on thera... 215K€ Cerrado

OBGate Creating an orthogonal gate to the brain 1M€ Cerrado

CNS2023-144443 Biotecnología 200K€ Cerrado

SAF2017-91909-EXP CONTROL DIFERENCIAL DEL TRANSPORTE DE VEHICULOS TERAPEUTICOS... 54K€ Cerrado

EIN2019-103356 PORTADOR POLIPEPTIDICO INTRANASAL PARA EL TRATAMIENTO DE PAT... 10K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2024-01-31
Fecha Fin: 2029-02-28

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto CNS disorders, e.g. brain cancer and Alzheimer’s disease, are the most common, debilitating, and underserved diseases. CNS drugs have historically suffered from considerably lower success rates during development than those for non-CNS indications. One of the major reasons is the presence of CNS barriers, including the blood-brain (BBB) and blood-cerebrospinal fluid (CSF) barrier. These blood-brain interfaces severely restrict the cerebral bioavailability of pharmaceutical compounds. While numerous attempts have been done to find methods to efficiently shuttle compounds over the BBB, less work has been done on blood-CSF crossers. Here, I hypothesize that targeting the blood-CSF barrier at the choroid plexus (ChP) is an attractive, innovative and underexplored strategy to deliver therapeutics to the brain. Indeed, this CNS barrier forms a unique interface between blood and CSF and delivery of therapeutics across the ChP epithelial cells may offer added-value for the treatment of CNS diseases. Recently, we could show that the blood-CSF barrier, via hijacking the FOLR1 pathway, is indeed a novel and exciting entry site to deliver therapeutics to the brain. Proof of concept data convincingly show that our in house generated anti-FOLR1 single domain antibody (VHH) is able to deliver a peptide into the brain. Undoubtfully, further validating the use of this VHH as brain shuttle could have major therapeutic implications. Here, I aim to investigate: (1) which cargos can be shuttled into (specific regions of) the brain, (2) which neurological disorders might be targeted and (3) whether other RMT targets at the blood-CSF barrier have similar brain targeting capacity. This project will finally reveal whether the blood-CSF barrier is an interesting entry route to the brain with therapeutic potential. Consequently, I infer that the data generated from this project may provide major impetus to the development of novel therapeutic strategies for the treatment of CNS diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores